The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer.

Researchers say lerociclib plus fulvestrant could become a new treatment option for HR+/HER2- advanced breast cancer, but lerociclib is not approved in the US.

Incorporating mpMRI into initial staging before TURBT reduces the time to correct treatment for patients with MIBC.

Baseline geriatric vulnerabilities and QOL scores are associated with survival after chemotherapy in older adults with metastatic pancreatic cancer, researchers found.

New research suggests that firstborn twins may have a greater risk of developing leukemia than second-born twins.

Researchers, federal employees, and members of the public have voiced concerns about restrictions recently placed on federal ...

Aspirin did not provide any clinical benefits in a cohort of patients with colorectal cancer who had no history of cardiovascular disease or stroke.

The FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice regulations for active pharmaceutical ingredients.

Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...

Policies that improve payer coverage, streamline authorization processes, and reduce cost-sharing burdens for medical equipment are urgently needed,” according to researchers.